Your browser doesn't support javascript.
loading
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation
Rory Henderson; Robert J Edwards; Katayoun Mansouri; Katarzyna Janowska; Victoria Stalls; Megan Kopp; Barton F Haynes; Priyamvada Acharya.
Affiliation
  • Rory Henderson; Duke University
  • Robert J Edwards; Duke University
  • Katayoun Mansouri; Duke University
  • Katarzyna Janowska; Duke University
  • Victoria Stalls; Duke University
  • Megan Kopp; Duke University
  • Barton F Haynes; Duke University
  • Priyamvada Acharya; Duke University
Preprint in English | bioRxiv | ID: ppbiorxiv-173765
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
The glycan shield of the beta-coronavirus (β-CoV) Spike (S) glycoprotein provides protection from host immune responses, acting as a steric block to potentially neutralizing antibody responses. The conformationally dynamic S-protein is the primary immunogenic target of vaccine design owing to its role in host-cell fusion, displaying multiple receptor binding domain (RBD) ‘up’ and ‘down’ state configurations. Here, we investigated the potential for RBD adjacent, N-terminal domain (NTD) glycans to influence the conformational equilibrium of these RBD states. Using a combination of antigenic screens and high-resolution cryo-EM structure determination, we show that an N-glycan deletion at position 234 results in a dramatically reduced population of the ‘up’ state RBD position. Conversely, glycan deletion at position N165 results in a discernable increase in ‘up’ state RBDs. This indicates the glycan shield acts not only as a passive hinderance to antibody meditated immunity but also as a conformational control element. Together, our results demonstrate this highly dynamic conformational machine is responsive to glycan modification with implications in viral escape and vaccine design.Competing Interest StatementThe authors have declared no competing interest.View Full Text
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2020 Document type: Preprint
...